Medical-conditions Novo Nordisk's Oral Semaglutide Shows Promise in Obesity Trial; Eli Lilly's Orforglipron Outperforms in Head-to-Head , and Administrator 2025 October 7
Science Business operations poised to commence following FDA approval , and Administrator 2025 September 19
Science Stock Investor Cathie Wood Experiences a Crash Resulting in Potential Gains Exceeding 300% , and Administrator 2025 September 3
stock-market Weight loss pharmaceutical giants Eli Lilly and Novo Nordisk are leading a transformation - Which pharmaceutical stock shows the most promise in weight loss domain? , and Administrator 2025 May 29
stock-market A potential Spanish TB vaccine with enhanced efficacy edges towards financial backing , and Administrator 2025 May 17
stock-market To stimulate increase in youth population, authorities propose increasing maximum age limit. , and Administrator 2025 May 6
